{{Rsnum
|rsid=1042489
|Gene=BIRC5
|Chromosome=17
|position=78224125
|Orientation=plus
|GMAF=0.3848
|Gene_s=BIRC5
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 23.9 | 40.7 | 35.4
| HCB | 13.9 | 48.9 | 37.2
| JPT | 11.5 | 44.2 | 44.2
| YRI | 19.0 | 52.4 | 28.6
| ASW | 8.8 | 43.9 | 47.4
| CHB | 13.9 | 48.9 | 37.2
| CHD | 19.3 | 44.0 | 36.7
| GIH | 14.9 | 43.6 | 41.6
| LWK | 13.6 | 49.1 | 37.3
| MEX | 13.8 | 55.2 | 31.0
| MKK | 11.0 | 49.7 | 39.4
| TSI | 16.7 | 44.1 | 39.2
| HapMapRevision=28
}}{{PMID Auto
|PMID=22214342
|Title=Association of polymorphisms in survivin gene with the risk of hepatocellular carcinoma in Chinese han population: a case control study
|OA=1
}}

{{PMID Auto
|PMID=20881643
|Title=Prognostic significance of survivin polymorphisms on non-small cell lung cancer survival.
}}

{{PMID Auto
|PMID=22037783
|Title=Prognostic impact of polymorphisms in the MYBL2 interacting genes in breast cancer.
}}

{{PMID Auto
|PMID=24098667
|Title=Association of Survivin Polymorphisms with Tumor Susceptibility: A Meta-Analysis
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}